Chris Claiborne, Millennium
S
Chris Claiborne
Senior Director, Oncology Chemistry, Millennium
BIGGEST HIT: 5 NMEs into trials in 3 years
KEY ROLE IN: Millennium's $8.8 billion Takeda payday
Already a rising star in grad school, Chris Claiborne spent seven years "in training" with Merck's discovery corps before jumping in 2002 to Millennium, then a promising startup in the Boston biocluster.
Chris Claiborne
Six years later, Claiborne, 40, has major bragging rights: five first-in-class compounds moved into trials in three years—including Velcade. "That was the first time I had to advocate for something transforming for the company—but knowing it might fail," he recalls. "Having the organization believe in my arguments transformed my interest in working in biotech."
If leading the preclinical lab has been a learning curve, Claiborne has proved a quick study—and all the credit goes to his boss, Chief Scientific Officer Joseph Bolen, he insists. "He has always emphasized the importance of culture among the scientists and spends every Friday in the lab." Drug discovery is certainly a team effort, but the entire industry took note of Claiborne's stunning six-year run when, last April, Takeda bought the biotech for a sweet $8.8 billion.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
